Kumar S D, Emery M J, Atkins N D, Danta I, Wanner A
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA.
Am J Respir Crit Care Med. 1998 Jul;158(1):153-6. doi: 10.1164/ajrccm.158.1.9712141.
As an inflammatory airway disease, asthma is expected to be associated with an increase in airway blood flow. We therefore compared airway mucosal blood flow (Qaw) among normal subjects (n = 11) and patients with stable asthma receiving (n = 13) or not receiving (n = 10) long-term inhaled glucocorticosteroid (GS) therapy. Qaw was calculated from the uptake of dimethyl ether in the anatomic dead space minus the most proximal 50 ml (DS), and expressed as blood flow per ml DS. Mean (+/- SE) Qaw was 38.5 +/- 5. 3 microl . min-1 . ml-1 in normals, 68.2 +/- 7.9 microl . min-1 . ml-1 in GS-naive asthmatics (p < 0.01), and 55.4 +/- 5.3 microl . min-1 . ml-1 in GS-treated asthmatics (p < 0.05). Ten minutes after administration of 180 microg albuterol by metered dose inhaler, mean Qaw increased by 83 +/- 26% in normal subjects (p < 0.01), but did not change significantly in GS-naive (+5 +/- 8%) or GS-treated (+32 +/- 15%) asthmatics. These results demonstrate that Qaw is increased in stable asthmatics and resistant to further increase by a standard inhaled dose of a beta-adrenergic agonist.
作为一种炎症性气道疾病,哮喘预计与气道血流增加有关。因此,我们比较了正常受试者(n = 11)以及接受(n = 13)或未接受(n = 10)长期吸入糖皮质激素(GS)治疗的稳定期哮喘患者的气道黏膜血流(Qaw)。Qaw通过计算解剖无效腔(减去最近端50 ml,即DS)中二甲醚的摄取量得出,并表示为每毫升DS的血流量。正常受试者的平均(±标准误)Qaw为38.5±5.3微升·分钟⁻¹·毫升⁻¹,未使用GS的哮喘患者为68.2±7.9微升·分钟⁻¹·毫升⁻¹(p < 0.01),使用GS治疗的哮喘患者为55.4±5.3微升·分钟⁻¹·毫升⁻¹(p < 0.05)。通过定量吸入器给予180微克沙丁胺醇10分钟后,正常受试者的平均Qaw增加了83±26%(p < 0.01),但未使用GS的哮喘患者(增加5±8%)或使用GS治疗的哮喘患者(增加32±15%)的Qaw无显著变化。这些结果表明,稳定期哮喘患者的Qaw增加,且对标准吸入剂量的β-肾上腺素能激动剂的进一步增加具有抗性。